Applied Spectral Imaging Inc (ASI), Carlsbad, Calif, and WaveSense Inc, Irvine, Calif, are integrating their platforms to provide a newly optimized molecular pathology solution.
ASI's GenASIs imaging and analysis instrument will be paired with WaveSense's EpiSEP cell recovery and enrichment solution to deliver an integrated cell-capturing solution and computerized instrument to detect, image, and analyze the captured cells.
"Our combined offering for molecular pathology and cytogenetics leverages the imaging and analysis accuracy, speed, and quality results of GenASIs with the improved workflow, flexibility, efficiency, and simplicity of EpiSEP and this, in turn, brings unparalleled value to our customers," says Limor Shiposh CEO, ASI.
Personalized medicine challenges labs to continuously evolve and expand their molecular pathology applications rapidly and cost-effectively, notes Chris Feistel CEO, WaveSense. He says the two companies' platforms provide a straightforward, versatile environment for optimizing existing applications or implementing new applications.
"The diagnostic specificity, diagnostic sensitivity, workflow efficiencies, and robustness that our combined platforms can assert on an application are tremendous," Feistel says. "The GenASIs platform is very accessible and user-friendly, it expertly complements the simplicity and ease of use of our EpiSEP platform. The new combined platform is ideally suited for containing, imaging, and analyzing paramagnetic labeled target cells within the EpiSEP slide."
The combined solution is effective in performing semiautomated FISH analysis of paramagnetic labeled target cells. Target cells may be retrieved, enriched, imaged, and analyzed in urine, bone marrow, blood, needle aspiration, abdominal ascites, lymph node, culture, and pleural effusion specimens.
GenASIs is FDA-cleared for FISH clinical applications such as ALK, UroVysion, HER2/neu, CEP XY, and Karyotyping. ASI complies with major regulatory requirements and international quality standards.